INGR initiated with Buy rating

What happened: Ingredion Incorporated (INGR) received a Buy rating from Oppenheimer, with a reduced price target of $126 ahead of Q1 results, while Deutsche Bank initiated coverage of Atai Life Sciences (ATAI) with a 'Buy' rating and a $12 price target, implying 320% upside. Separately, Bernstein initiated coverage of Roivant Sciences (ROIV) with an Outperform rating and a $35 price target, citing potential from upcoming clinical readouts. Ingredion also received a Buy rating from Benchmark.

Market impact: These analyst upgrades reflect optimism in the food and biotech sectors. Ingredion, a key player in the food industry, is expected to report healthy Q1 results, driving investor confidence in the sector. Atai and Roivant, both involved in emerging fields (psychiatry and drug development respectively), have seen analyst recognition of their growth potential, pushing their stocks higher.

What to watch next: Ingredion's Q1 earnings report on May 5 will confirm analyst expectations and potentially drive further movement in the stock. For Atai and Roivant, upcoming clinical readouts in Q2 and Q3 respectively will be crucial catalysts, as positive results could validate analysts' bullish stances and push stocks higher.